Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 19Lung Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Pancreatic Neoplasms 3Neoplasm Metastasis 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Gastrointestinal Stromal Tumors 2Breast Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1Thyroid Neoplasms 1Solid Tumor 1Soft Tissue Neoplasms 1Skin Neoplasms 1Peripheral Nervous System Neoplasms 1Non-small Cell Carcinoma 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia 1Gliosarcoma 1

Interventions

encorafenib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced BRAF Mutant Cancers × binimetinib × Clear all
NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 9 charts

Advanced BRAF Mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡